Y
ask why

Latest research

Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.

Oncology · Lancet Oncol · 2026-10-25

Phase 3 trial, 231 patients with locally advanced rectal cancer: short-course radiotherapy, camrelizumab and CAPOX vs long-course chemoradiotherapy then CAPOX. Primary pCR 39.8% vs 15.3%; interim 3-year event-free survival 91.3% vs 77.4% (HR 0.33).

RCTn = 231
Tao et al. Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial
Oncology · Lancet · 2026-10-24

In 970 patients with refractory metastatic colorectal cancer in Japan, a 14-day trifluridine-tipiracil plus bevacizumab schedule was non-inferior to the 28-day schedule for overall survival (median 11·3 vs 10·3 months; HR 0·93), with less grade ≥3 neutropenia (13% vs 39%).

RCTn = 970
Sakakida et al. 14-day versus 28-day trifluridine-tipiracil plus bevacizumab for refractory metastatic colorectal cancer (PRABITAS): a pragmatic, multicentre, open-label, randomised, phase 3, non-inferiority trial in Japan
Oncology · Lancet Oncol · 2026-08-23

In early and intermediate-stage rectal cancer patients choosing organ preservation, 12-month TME-free survival was 78.5% with long-course chemoradiotherapy vs 60.6% with short-course radiotherapy (HR 1.90) in an early analysis; the 30-month primary endpoint is awaited.

RCTn = 409
Bach et al. Chemoradiotherapy versus short-course radiotherapy for response-adapted organ preservation in early-stage and intermediate-stage rectal cancer (STAR-TREC): 12-month results of an international, multicentre, open-label, parallel-group, randomised, phase 2/3 trial

Sign in to react

Enter your email and we send a one-time link. No password.

Your name and role

These appear beside any methods concern you post and on your profile page.